Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Yi Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9357-1205; OpenAlex author ID A5035770690. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper

Papers 7

  1. Correction: hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancr… Co-author DOI 10.1186/s12943-024-01937-9↗
  2. Section the tumor and divest the arterial sheath in a patient with locally advanced pancreatic cancer. Last author DOI 10.1016/j.asjsur.2022.07.125↗
  3. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal… Co-author DOI 10.1186/s12943-023-01887-8↗
  4. Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenoc… Co-author DOI 10.1002/jcla.24784↗
  5. The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathw… Co-author DOI 10.1186/s12943-022-01647-0↗
  6. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. Co-author DOI 10.2147/dddt.s261017↗
  7. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer. Co-author DOI 10.3892/or.2017.6050↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zeqiang Ren · 3 shared papers, 2017–2024 · strength 0.42
  2. Lei Xu · 2 shared papers, 2023–2024 · strength 0.35
  3. Pengbo Zhang · 2 shared papers, 2023–2024 · strength 0.35
  4. Dan Cao · 1 shared paper, 2023 · strength 0.26
  5. Bole Tian · 1 shared paper, 2023 · strength 0.26
  6. Yi Jin · 1 shared paper, 2023 · strength 0.26
  7. Xiao Ma · 1 shared paper, 2024 · strength 0.19
  8. Bin Zhong · 1 shared paper, 2022 · strength 0.16
  9. Xiaomeng Liu · 1 shared paper, 2022 · strength 0.16
  10. Hongquan Wang · 1 shared paper, 2022 · strength 0.16
  11. Bo Tang · 1 shared paper, 2022 · strength 0.16
  12. Yan Wang · 1 shared paper, 2022 · strength 0.16
  13. ZhongHu Li · 1 shared paper, 2022 · strength 0.16
  14. Shihui Lai · 1 shared paper, 2022 · strength 0.16
  15. Qi Gong · 1 shared paper, 2022 · strength 0.16
  16. Chen Yang · 1 shared paper, 2020 · strength 0.11
  17. Xing Huang · 1 shared paper, 2020 · strength 0.11
  18. Chao Wu · 1 shared paper, 2020 · strength 0.11
  19. Li Wang · 1 shared paper, 2020 · strength 0.11
  20. Bole Tian · 1 shared paper, 2020 · strength 0.11
  21. Li Liu · 1 shared paper, 2017 · strength 0.06
  22. Pengbo Zhang · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.